![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » SANOFI-AVENTIS BEATS FORECASTS
SANOFI-AVENTIS BEATS FORECASTS
November 8, 2005
Sanofi-Aventis beat third-quarter forecasts as the French pharmaceuticals company's older heart disease and cancer drugs, as well as influenza vaccines continued to sell well. Net income rose 29 per cent to €1.92bn ($2.27bn), excluding acquisition costs associated with Sanofi's takeover of Aventis last year and sales rose 12 per cent to €7.2bn. Shares rose 2.8 per cent by mid-day to €69.80 as Sanofi's results beat analysts' expectations.
MSNBC (http://msnbc.msn.com/id/9966220/)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct